Christopher Richard Anzalone - 16 Dec 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
16 Dec 2022
Net transactions value
$0
Form type
4
Filing time
20 Dec 2022, 18:09:51 UTC
Previous filing
29 Sep 2022
Next filing
05 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Award $0 +18,375 +0.53% $0.000000 3,486,689 16 Dec 2022 Direct F1
transaction ARWR Common Stock Award $0 +234,025 +6.7% $0.000000 3,720,714 20 Dec 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of stock which vested on the date of issuance.
F2 Includes 93,610 shares underlying restricted stock units, which will vest in four equal installments, with a commencement date of 12/20/22. Includes 140,415 underlying restricted stock units, that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part of in whole.
F3 Includes a total of 1,789,697 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.